Table 4.
Multivariable logistic regression analyses for odds ratios of lipid testing and statin prescription for SLE cohort
| Lipid Testing | Statin Prescription | |||||
|---|---|---|---|---|---|---|
| SLE Cohort* | SLE Cohort Excluding Baseline CVD† | SLE Cohort with Baseline CVD‡ | SLE Cohort* | SLE Cohort Excluding Baseline CVD† | SLE Cohort with Baseline CVD‡ | |
| N=25,950 | N=22,221 | N=3,729 | N=25,950 | N=22,221 | N=3,729 | |
| Odds ratio (95%CI) | Odds ratio (95%CI) | Odds ratio (95%CI) | Odds ratio (95%CI) | Odds ratio (95%CI) | Odds ratio (95%CI) | |
| Age | ||||||
| 18–39 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| 40–49 | 1.28 (1.19–1.38) | 1.27 (1.17–1.37) | 1.38 (1.23–1.69) | 1.71 (1.53–1.91) | 1.71 (1.51–1.95) | 1.68 (1.33–2.12) |
| 50–65 | 1.57 (1.46–1.69) | 1.57 (1.45–1.71) | 1.58 (1.30–1.92) | 3.15 (2.83–3.50) | 3.42 (3.03–3.86) | 2.41 (1.93–3.01) |
| Sex | ||||||
| Female | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| Male | 1.04 (0.93–1.17) | 1.02 (0.90–1.16) | 1.12 (0.88–1.44) | 1.23 (1.06–1.43) | 1.23 (1.03–1.47) | 1.20 (0.91–1.57) |
| Race/ethnicity | ||||||
| White | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| Black | 1.09 (1.01–1.18) | 1.10 (1.02–1.19) | 1.04 (0.87–1.26) | 0.87 (0.79–0.97) | 0.90 (0.79–1.01) | 0.81 (0.66–0.99) |
| Hispanic | 1.37 (1.25–1.50) | 1.37 (1.24–1.52) | 1.34 (1.05–1.72) | 1.06 (0.93–1.21) | 1.11 (0.95–1.29) | 0.93 (0.71–1.23) |
| Asian | 1.86 (1.58–2.19) | 1.85 (1.56–2.20) | 1.88 (1.15–3.06) | 1.56 (1.25–1.95) | 1.68 (1.32–2.14) | 1.08 (0.62–1.87) |
| American Indian/Alaskan Native | 0.74 (0.54–1.03) | 0.80 (0.57–1.12) | 0.35 (0.10–1.25) | 0.57 (0.34–0.96) | 0.58 (0.33–1.03) | 0.51 (0.14–1.81) |
| Outpatient visitsc | 1.06 (1.05–1.07) | 1.06 (1.05–1.07) | 1.06 (1.05–1.08) | 1.00 (0.99–1.01) | 0.99 (0.98–1.00) | 1.02 (1.00–1.03) |
| Number of medicationsc | 1.04 (1.04–1.05) | 1.04 (1.04–1.05) | 1.05 (1.04–1.06) | 1.07 (1.06–1.07) | 1.07 (1.06–1.07) | 1.06 (1.05–1.07) |
| Glucocorticoid use ≥ 10 mg/day ever | 1.07 (1.00–1.15) | 1.09 (1.01–1.17) | 1.01 (0.84–1.20) | 1.22 (1.11–1.34) | 1.21 (1.08–1.35) | 1.24 (1.02–1.50) |
| SLE risk adjustment indexc | 0.98 (0.96–1.00) | 0.98 (0.95–1.00) | 0.98 (0.95–1.01) | 0.98 (0.96–1.01) | 1.00 (0.97–1.04) | 0.98 (0.95–1.01) |
| Presence of CVD | 1.06 (0.97–1.17) | - | - | 2.04 (1.82–2.29) | - | - |
| Presence LN | 1.39 (1.29–1.51) | 1.44 (1.32–1.57) | 1.22 (1.02–1.47) | 2.39 (2.16–2.65) | 2.88 (2.55–3.24) | 1.44 (1.18–1.75) |
SLE cohort multivariable logistic regression analysis adjusted for age, sex, race, US region of residence, socioeconomic status, # outpatient visits, # medications, glucocorticoid use, SLE risk adjustment index, presence of CVD, presence of LN
SLE Cohort sensitivity analysis excluding patients with baseline presence of CVD, multivariable logistic regression analysis adjusting for age, sex, race, US region of residence, socioeconomic status, # outpatient visits, # medications, glucocorticoid use, SLE risk adjustment index, presence of LN
SLE Cohort sensitivity analysis including only patients with baseline presence of CVD, multivariable logistic regression analysis adjusting for age, sex, race, US region of residence, socioeconomic status, # outpatient visits, # medications, glucocorticoid use, SLE risk adjustment index, presence of LN
Abbreviations: SLE, systemic lupus erythematosus; CVD, cardiovascular disease; LN, lupus nephritis